Literature DB >> 32931838

Varenicline rescues nicotine-induced decrease in motivation for sucrose reinforcement.

Erin Hart1, Daniel Hertia1, Scott T Barrett2, Sergios Charntikov1.   

Abstract

Varenicline is one of the top medications used for smoking cessation and is often prescribed before termination of nicotine use. The effect of this combined nicotine and varenicline use on the reward system and motivation for primary reinforcement is underexplored. The goal of this study was to assess the effects of nicotine and varenicline on motivation for a food reinforcer. In Experiment 1, we first assessed the responding for sucrose after pretreatment with nicotine (0, 0.1, or 0.4 mg/kg) and varenicline (0.0, 0.1, 1.0 mg/kg) using a behavioral economics approach. The responding for sucrose was then assessed using a progressive ratio schedule of reinforcement after pretreatment with all possible combinations of nicotine and varenicline doses. In Experiment 2, rats were assessed for the consumption of sucrose in home cages after pretreatment with nicotine and varenicline. We found that (a) nicotine decreased economic demand for sucrose, (b) varenicline rescued nicotine-induced reduction in economic demand for sucrose, and (c) history of varenicline treatment predicted responding for sucrose on a progressive ratio schedule of reinforcement where rats with a history of varenicline treatment responded significantly lower for sucrose across nicotine doses than rats that had not been exposed to varenicline. The results of Experiment 2 largely confirmed that nicotine decreases motivation for sucrose using a passive consumption protocol and that varenicline rescues this effect. Overall, these findings suggest that varenicline interacts with the effects of nicotine by restoring nicotine-induced reduction in motivation for appetitive rewards.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Economic demand; Nicotine; Nicotine cessation; Nicotine use; Varenicline

Mesh:

Substances:

Year:  2020        PMID: 32931838      PMCID: PMC7722240          DOI: 10.1016/j.bbr.2020.112887

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  75 in total

Review 1.  Prevention of relapse after quitting smoking: a systematic review of trials.

Authors:  Tim Lancaster; Peter Hajek; Lindsay F Stead; Robert West; Martin J Jarvis
Journal:  Arch Intern Med       Date:  2006-04-24

Review 2.  The economics of drug abuse: a quantitative assessment of drug demand.

Authors:  Steven R Hursh; Chad M Galuska; Gail Winger; James H Woods
Journal:  Mol Interv       Date:  2005-02

3.  Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

Authors:  Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves
Journal:  JAMA       Date:  2006-07-05       Impact factor: 56.272

Review 4.  The neuronal pathways mediating the behavioral and addictive properties of nicotine.

Authors:  David J K Balfour
Journal:  Handb Exp Pharmacol       Date:  2009

5.  Nicotine amplifies reward-related dopamine signals in striatum.

Authors:  Margaret E Rice; Stephanie J Cragg
Journal:  Nat Neurosci       Date:  2004-05-16       Impact factor: 24.884

6.  In vivo regulation of [3H]acetylcholine recognition sites in brain by nicotinic cholinergic drugs.

Authors:  R D Schwartz; K J Kellar
Journal:  J Neurochem       Date:  1985-08       Impact factor: 5.372

7.  Reinforcement enhancing effect of nicotine and its attenuation by nicotinic antagonists in rats.

Authors:  Xiu Liu; Matthew I Palmatier; Anthony R Caggiula; Eric C Donny; Alan F Sved
Journal:  Psychopharmacology (Berl)       Date:  2007-07-08       Impact factor: 4.530

8.  A behavioral economic analysis of the value-enhancing effects of nicotine and varenicline and the role of nicotinic acetylcholine receptors in male and female rats.

Authors:  Scott T Barrett; Trevor N Geary; Amy N Steiner; Rick A Bevins
Journal:  Behav Pharmacol       Date:  2018-09       Impact factor: 2.293

9.  Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control.

Authors:  Jelte A Wouda; Danai Riga; Wendy De Vries; Mathijs Stegeman; Yvar van Mourik; Dustin Schetters; Anton N M Schoffelmeer; Tommy Pattij; Taco J De Vries
Journal:  Psychopharmacology (Berl)       Date:  2011-02-18       Impact factor: 4.530

10.  Diminishing benefit of smoking cessation medications during the first year: a meta-analysis of randomized controlled trials.

Authors:  Laura J Rosen; Tal Galili; Jeffrey Kott; Mark Goodman; Laurence S Freedman
Journal:  Addiction       Date:  2018-01-29       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.